Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

210.63
+2.811.35%
Volume:428.39K
Turnover:89.97M
Market Cap:11.03B
PE:-55.89
High:211.22
Open:207.97
Low:205.76
Close:207.82
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.81
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:132.44
PE(LYR):-57.20

Loading ...

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Reuters
·
Sep 04

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says

MT Newswires Live
·
Sep 01

Axsome Therapeutics Price Target Maintained with a $290.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Axsome pullback brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Aug 31

Axsome Therapeutics, - Doses First Patient in Summit Phase 3 Trial of Axs-05 for Smoking Cessation

THOMSON REUTERS
·
Aug 31

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

GlobeNewswire
·
Aug 31

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Rising Revenue And Widening Net Losses

Simply Wall St.
·
Aug 24

Axsome Therapeutics (AXSM) Stock Still Trades Below Fair Value On Sales

Simply Wall St.
·
Aug 21

UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating

MT Newswires Live
·
Aug 12

Liquidia Q2 Revenue Jumps on Yutrepia Sales

Reuters
·
Aug 12

Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says

MT Newswires Live
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Axsome Therapeutics (AXSM) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Aug 11

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Benzinga Earnings
·
Aug 11

Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital

TIPRANKS
·
Aug 11

Axsome Therapeutics Price Target Raised to $256.00/Share from $255.00 by Wells Fargo

Dow Jones
·
Aug 11

Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley

TIPRANKS
·
Aug 11

Fennec Pharmaceuticals Q2 Sales Rise on Pedmark Demand

Reuters
·
Aug 11

RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating

MT Newswires Live
·
Aug 11